Dirk G. Dechering

Dirk G. Dechering

Auto-generated profile, based on publicly available information

Dirk G. Dechering

Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in EP Europace
Verified
Journal Article
Open access
PDF file
Gerrit FrommeyerGerrit Frommeyer
Gerrit Frommeyer
JGJonas Garthmann
Jonas Garthmann
CEChristian Ellermann
Christian Ellermann
DDDirk G Dechering
Dirk G Dechering
SKSimon Kochhäuser
Simon Kochhäuser
LELars Eckardt
Lars Eckardt
Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias. We aimed at investigating mexiletine in experimental models of atrial fibrillation (AF) as well as in long-QT- (LQTS) and short-QT-syndrome (SQTS). In 15 isolated rabbit hearts, erythromycin (300 µM) was infused for simulation of long-QT-2-syndrome. In further 13 hearts, veratridine was administered to simulate long-QT-3-syndrome. Both drugs induced a significant QT-prolongation (erythromycin: +87 ms, P < 0.01; veratridine: +19 ms, P < 0.05) and increased dispersion of repolarization (erythromycin: +55 ms, P < 0.01; veratridine +31 ms, P < 0.01). Additional infusion of mexiletine (25 µM) resulted in a significant reduction of dispersion (erythromycin: −43 ms, P < 0.01; veratridine: −26 ms, P < 0.05). Reproducible induction of torsade de pointes was observed in 13 of 15 erythromycin-treated hearts (192 episodes) and 6 of 13 veratridine-treated hearts (36 episodes). Additional infusion of mexiletine significantly reduced ventricular tachycardia (VT) incidence. With mexiletine, only 3 of 15 erythromycin-treated hearts (27 episodes) and 1 of 13 veratridine-treated hearts (2 episodes) presented polymorphic VT. In additional 9 hearts, the IK-ATP-channel-opener pinacidil was employed to simulate SQTS and significantly abbreviated ventricular repolarization (QT-interval: −18 ms, P < 0.05) and enhanced induction of ventricular fibrillation (VF). Mexiletine reversed the effects of pinacidil, increase refractory period (+127 ms, P < 0.01) and significantly suppressed induction of VF. In further 13 hearts AF was induced by combined treatment with acetylcholine/isoproterenol. Mexiletine also increased atrial refractory period (+80 ms, P < 0.01) and thereby effectively suppressed atrial fibrillation. Acute infusion of mexiletine significantly reduced the occurrence of polymorphic VT in the presence of pharmacologically simulated LQTS. Furthermore, mexiletine demonstrated potent antiarrhythmic properties in a model of SQTS and in AF.

4 January 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
Gerrit FrommeyerGerrit Frommeyer
Gerrit Frommeyer
JKJulius Krawczyk
Julius Krawczyk
CEChristian Ellermann
Christian Ellermann
NBNils Bögeholz
Nils Bögeholz
SKSimon Kochhäuser
Simon Kochhäuser
LELars Eckardt
Lars Eckardt

10 November 2015 in Circulation
Verified
Journal Article
Closed access
SKSimon Kochhaeuser
Simon Kochhaeuser
DDDirk Dechering
Dirk Dechering
KTKathleen Trought
Kathleen Trought
PHPhilip Hache
Philip Hache
THTanjah Haig-Carter
Tanjah Haig-Carter
AVAtul Verma
Atul Verma